Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 46

Cited In for PubMed (Select 62019)

1.

Complement and HIV-I infection/HIV-associated neurocognitive disorders.

Liu F, Dai S, Gordon J, Qin X.

J Neurovirol. 2014 Apr;20(2):184-98. doi: 10.1007/s13365-014-0243-9. Epub 2014 Mar 18. Review.

2.

The structural immunology of antibody protection against West Nile virus.

Diamond MS, Pierson TC, Fremont DH.

Immunol Rev. 2008 Oct;225:212-25. doi: 10.1111/j.1600-065X.2008.00676.x. Review.

3.

Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus.

Johnson JB, Capraro GA, Parks GD.

Virology. 2008 Jun 20;376(1):112-23. doi: 10.1016/j.virol.2008.03.022. Epub 2008 Apr 28.

5.

Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity.

Jayasekera JP, Moseman EA, Carroll MC.

J Virol. 2007 Apr;81(7):3487-94. Epub 2007 Jan 3.

6.

Porcine endogenous retrovirus transmission characteristics of galactose alpha1-3 galactose-deficient pig cells.

Quinn G, Wood JC, Ryan DJ, Suling KM, Moran KM, Kolber-Simonds DL, Greenstein JL, Schuurman HJ, Hawley RJ, Patience C.

J Virol. 2004 Jun;78(11):5805-11.

7.

PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum.

Croyle MA, Callahan SM, Auricchio A, Schumer G, Linse KD, Wilson JM, Brunner LJ, Kobinger GP.

J Virol. 2004 Jan;78(2):912-21.

9.

The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent.

DePolo NJ, Harkleroad CE, Bodner M, Watt AT, Anderson CG, Greengard JS, Murthy KK, Dubensky TW Jr, Jolly DJ.

J Virol. 1999 Aug;73(8):6708-14.

10.
12.

Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell.

Takeuchi Y, Cosset FL, Lachmann PJ, Okada H, Weiss RA, Collins MK.

J Virol. 1994 Dec;68(12):8001-7.

13.

A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody.

Rother RP, Fodor WL, Springhorn JP, Birks CW, Setter E, Sandrin MS, Squinto SP, Rollins SA.

J Exp Med. 1995 Nov 1;182(5):1345-55.

14.

Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.

Schmitz J, Zimmer JP, Kluxen B, Aries S, Bögel M, Gigli I, Schmitz H.

J Clin Invest. 1995 Sep;96(3):1520-6.

15.

Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1.

Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla-Pazner S, Ghassemi M, Rooney IA, Atkinson JP, Spear GT.

J Exp Med. 1995 Aug 1;182(2):501-9.

16.

Activation of complement by cells infected with respiratory syncytial virus.

Smith TF, McIntosh K, Fishaut M, Henson PM.

Infect Immun. 1981 Jul;33(1):43-8.

17.

Nonspecific reactions in the hemagglutination inhibition test for detection of rubella antibodies.

Budzko DB, Jelinek DF, Wilcke BW Jr.

J Clin Microbiol. 1981 May;13(5):818-23.

18.

The complement system: its importance in the host response to viral infection.

Hirsch RL.

Microbiol Rev. 1982 Mar;46(1):71-85. Review. No abstract available.

19.

Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies.

Vanguri P, Koski CL, Silverman B, Shin ML.

Proc Natl Acad Sci U S A. 1982 May;79(10):3290-4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk